<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002539</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-80931</org_study_id>
    <secondary_id>EOI-80931</secondary_id>
    <secondary_id>EORTC-80931</secondary_id>
    <secondary_id>MRC-BO06</secondary_id>
    <secondary_id>EU-93024</secondary_id>
    <nct_id>NCT00002539</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma</brief_title>
  <official_title>A RANDOMISED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT GRANULOCYTE COLONY-STIMULATING FACTOR IN OPERABLE OSTEOSARCOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of&#xD;
      immune cells found in bone marrow or peripheral blood and may help a person's immune system&#xD;
      recover from the side effects of chemotherapy. It is not yet known whether chemotherapy and&#xD;
      surgery plus G-CSF is more effective than chemotherapy and surgery alone in treating patients&#xD;
      with osteosarcoma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness combination chemotherapy and&#xD;
      surgery with or without G-CSF in treating patients who have newly diagnosed osteosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall and disease-free survival of patients with newly diagnosed&#xD;
           osteosarcoma of the extremity treated with conventional vs intensive cisplatin and&#xD;
           doxorubicin with or without filgrastim (G-CSF) before and after definitive surgery.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive conventional doxorubicin (DOX) IV over 4 hours on days 1-3 and&#xD;
           cisplatin (CDDP) IV continuously on day 1. Treatment continues every 3 weeks for 2&#xD;
           courses. At week 6, patients undergo amputation or local resection based on pretherapy&#xD;
           imaging and response to chemotherapy. Beginning 2 weeks after surgery, patients receive&#xD;
           4 additional courses of conventional chemotherapy.&#xD;
&#xD;
        -  Arm II: Patients receive intensive DOX and CDDP as above on day 1 plus filgrastim&#xD;
           (G-CSF) subcutaneously on days 4-13. Treatment continues every 2 weeks for 3 courses. At&#xD;
           week 6, patients undergo definitive surgery as in arm I. Beginning 2 weeks after&#xD;
           surgery, patients receive 3 additional courses of intensive DOX and CDDP with G-CSF.&#xD;
&#xD;
      Patients who experience disease progression during preoperative chemotherapy undergo surgery&#xD;
      earlier than scheduled and complete all scheduled chemotherapy (6 courses) after surgery, at&#xD;
      the discretion of the surgeon and oncologist. Within 4 weeks after limb-sparing procedure,&#xD;
      patients with inadequate margins undergo amputation, followed 2 weeks later by chemotherapy.&#xD;
&#xD;
      Patients are followed monthly for 6 months, every 2 months for 6 months, every 3 months for 1&#xD;
      year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1993</start_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">214</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven resectable osteosarcoma of the long bone of an extremity&#xD;
&#xD;
          -  No parosteal (juxtacortical), periosteal, Pagetoid, or post-irradiation sarcoma&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  40 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3 OR&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.2 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Glomerular filtration rate at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of cardiac dysfunction&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy except basal cell skin cancer OR&#xD;
&#xD;
          -  Carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne A. Nooij, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian J. Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels (Bruxelles)</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels (Bruxelles)</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Kommunehospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emma Kinderziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL-1100 DE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil-Centro de Lisboa</name>
      <address>
        <city>Lisbon</city>
        <zip>1099-023 Codex</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital and Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology, Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Saudi Arabia</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007 Jan 17;99(2):112-28. doi: 10.1093/jnci/djk015.</citation>
    <PMID>17227995</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis IJ, Nooij M: Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: a randomised controlled trial conducted by the European Osteo Sarcoma Intergroup (ISRCTN 86294690). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3281, 816, 2003.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

